SCHEMBL4408514

SCHEMBL4408514

CCn1c(=N)c(-c2cc(OC)cc(C(=O)OC)c2)cc2cnc(SC)nc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.36
FGFR1 P11362 4/20 0.35
FGFR4 P22455 2/20 0.35
FGFR2 P21802 1/20 0.35
FGFR3 P22607 1/20 0.35
KDM4E B2RXH2 4/20 0.35
TSHR P16473 4/20 0.35
ALDH1A1 P00352 4/20 0.35
HSD17B10 Q99714 2/20 0.35
LMNA P02545 2/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
P2RX3 P56373 1/20 0.32
LYN P07948 1/20 0.32
SRC P12931 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712139 0.88 FGFR1 (0.41) FGFR1FGFR4FGFR2FGFR3GAA
SCHEMBL4331064 0.81 FGFR4 (0.42) FGFR1FGFR4FGFR2FGFR3LYN
SCHEMBL4397120 0.79 LYN (0.38) FGFR1FGFR4KDM4ETSHRALDH1A1
SCHEMBL4399224 0.79 FGFR4 (0.41) FGFR1FGFR4FGFR2FGFR3TSHR
SCHEMBL4713056 0.78 FGFR4 (0.51) FGFR1FGFR4FGFR2FGFR3LYN
SCHEMBL4710510 0.76 FGFR1 (0.39) FGFR1FGFR4FGFR2FGFR3SRC
SCHEMBL4710511 0.76 FGFR1 (0.39) FGFR1FGFR4FGFR2FGFR3SRC
SCHEMBL23328289 0.73 FGFR1 (0.45) FGFR1FGFR4FGFR2FGFR3GAA
SCHEMBL1135023 0.73 JAK3 (0.41) MEN1KMT2ANEK1
SCHEMBL4681018 0.72 FGFR4 (0.46) FGFR1FGFR4FGFR2FGFR3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
WO-2007136465-A2 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS PTK2B, SGK2, FRK TP53 1246/4885FGFR1 92/4885FGFR4 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.